Suppression of hepatic gluconeogenesis in long-term Troglitazone treated diabetic KK and C57BL/KsJ-db/db mice - PubMed (original) (raw)
Suppression of hepatic gluconeogenesis in long-term Troglitazone treated diabetic KK and C57BL/KsJ-db/db mice
T Fujiwara et al. Metabolism. 1995 Apr.
Abstract
The orally effective antidiabetic agent Troglitazone (CS-045) exerts hypoglycemic effects in various insulin-resistant obese and/or diabetic animals. Since increased hepatic gluconeogenesis is a major cause of hyperglycemia in these diabetic animals, we evaluated the effect of long-term Troglitazone treatment on hepatic gluconeogenesis. Troglitazone was administered for 7 days to normal ddY mice, diabetic KK mice, diabetic C57BL/KsJ-db/db mice, and its heterozygote, db/+ mice, as a 0.1% or 0.2% food admixture. Troglitazone significantly decreased plasma glucose in diabetic KK and db/db mice, but not in normal ddY and db/+ mice. 14C incorporation into blood glucose from NaH14CO3 was measured to assess hepatic gluconeogenesis in diabetic KK and normal ddY mice. Hepatic gluconeogenesis was significantly increased in diabetic KK mice (P < .01) as compared with normal mice, and was significantly suppressed (P < .05) after 7 days of Troglitazone treatment (approximately 200 mg/kg/d). Glucose-6-phosphate (G6P) and fructose-6-phosphate (F6P) were significantly decreased but fructose-1,6-bisphosphate (FBP) was not significantly increased in the liver of diabetic db/db mice treated with Troglitazone for 7 days (approximately 80 mg/kg/d) as compared with control db/db mice. These changes in G6P, F6P, and FBP corresponded with the activity of fructose-1,6-bisphosphatase (Fru-1,6P2ase) and 6-phosphofructo-1-kinase (6-PF-1K), which determined the content of F6P and FBP. Namely, Fru-1,6P2ase was significantly decreased in Troglitazone-treated db/db mice as compared with control mice, whereas 6-PF-1K activity was not affected by Troglitazone treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
- Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
Plosker GL, Faulds D. Plosker GL, et al. Drugs. 1999 Mar;57(3):409-38. doi: 10.2165/00003495-199957030-00014. Drugs. 1999. PMID: 10193691 Review. - Dehydroepiandrosterone suppresses the elevated hepatic glucose-6-phosphatase and fructose-1,6-bisphosphatase activities in C57BL/Ksj-db/db mice: comparison with troglitazone.
Aoki K, Saito T, Satoh S, Mukasa K, Kaneshiro M, Kawasaki S, Okamura A, Sekihara H. Aoki K, et al. Diabetes. 1999 Aug;48(8):1579-85. doi: 10.2337/diabetes.48.8.1579. Diabetes. 1999. PMID: 10426376 - Dehydroepiandrosterone suppresses elevated hepatic glucose-6-phosphatase mRNA level in C57BL/KsJ-db/db mice: comparison with troglitazone.
Aoki K, Kikuchi T, Mukasa K, Ito S, Nakajima A, Satoh S, Okamura A, Sekihara H. Aoki K, et al. Endocr J. 2000 Dec;47(6):799-804. doi: 10.1507/endocrj.47.799. Endocr J. 2000. PMID: 11228057 - Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice.
Fujiwara T, Wada M, Fukuda K, Fukami M, Yoshioka S, Yoshioka T, Horikoshi H. Fujiwara T, et al. Metabolism. 1991 Nov;40(11):1213-8. doi: 10.1016/0026-0495(91)90218-l. Metabolism. 1991. PMID: 1943750 - Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
Johnson MD, Campbell LK, Campbell RK. Johnson MD, et al. Ann Pharmacother. 1998 Mar;32(3):337-48. doi: 10.1345/aph.17046. Ann Pharmacother. 1998. PMID: 9533065 Review.
Cited by
- Use of dicarboxylic acids in type 2 diabetes.
Mingrone G, Castagneto-Gissey L, Macé K. Mingrone G, et al. Br J Clin Pharmacol. 2013 Mar;75(3):671-6. doi: 10.1111/j.1365-2125.2012.04177.x. Br J Clin Pharmacol. 2013. PMID: 22242741 Free PMC article. Review. - Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
Plosker GL, Faulds D. Plosker GL, et al. Drugs. 1999 Mar;57(3):409-38. doi: 10.2165/00003495-199957030-00014. Drugs. 1999. PMID: 10193691 Review. - Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.
Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, Kadowaki T. Okuno A, et al. J Clin Invest. 1998 Mar 15;101(6):1354-61. doi: 10.1172/JCI1235. J Clin Invest. 1998. PMID: 9502777 Free PMC article. - Can the electrophysiological action of rosiglitazone explain its cardiac side effects?
Szebeni A, Szentandrássy N, Pacher P, Simkó J, Nánási PP, Kecskeméti V. Szebeni A, et al. Curr Med Chem. 2011;18(24):3720-8. doi: 10.2174/092986711796642364. Curr Med Chem. 2011. PMID: 21774756 Free PMC article. - Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones.
Hevener AL, Olefsky JM, Reichart D, Nguyen MT, Bandyopadyhay G, Leung HY, Watt MJ, Benner C, Febbraio MA, Nguyen AK, Folian B, Subramaniam S, Gonzalez FJ, Glass CK, Ricote M. Hevener AL, et al. J Clin Invest. 2007 Jun;117(6):1658-69. doi: 10.1172/JCI31561. Epub 2007 May 24. J Clin Invest. 2007. PMID: 17525798 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous